CBIO Catalyst Biosciences Inc.

6.64
-0.08  -1%
Previous Close 6.72
Open 6.57
Price To Book 0.98
Market Cap 79,951,144
Shares 12,040,835
Volume 33,556
Short Ratio
Av. Daily Volume 604,412
Stock charts supplied by TradingView

NewsSee all news

  1. Catalyst Biosciences Announces Oral and Poster Presentations at the 13th Annual EAHAD Congress

    SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced one oral and three poster presentations at the 13th Annual Congress of the European Association

  2. Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding

  3. Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration

    SOUTH SAN FRANCISCO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced it has entered into a global license and collaboration agreement with Biogen Inc. (NASDAQ:BIIB)

  4. Catalyst Biosciences Presents Two Posters on MarzAA at the 61st Annual American Society of Hematology Conference

    SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding

  5. Catalyst Biosciences to Present at the Stifel Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to commence in 2020.
Marzeptacog alfa
Hemophilia
Phase 2b presentation at EAHAD February 7, 2020 at 8:30 am – 10:00 am CET.
Dalcinonacog alfa – DalcA
Hemophilia B
Phase 1 PK data due 2020.
Marzeptacog alfa
Hemophilia

Latest News

  1. Catalyst Biosciences Announces Oral and Poster Presentations at the 13th Annual EAHAD Congress

    SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced one oral and three poster presentations at the 13th Annual Congress of the European Association

  2. Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding

  3. Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration

    SOUTH SAN FRANCISCO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced it has entered into a global license and collaboration agreement with Biogen Inc. (NASDAQ:BIIB)

  4. Catalyst Biosciences Presents Two Posters on MarzAA at the 61st Annual American Society of Hematology Conference

    SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding

  5. Catalyst Biosciences to Present at the Stifel Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will

  6. Catalyst Biosciences Reports Third Quarter 2019 Operating & Financial Results and Provides a Corporate Update

    SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced its operating and financial results for the third quarter ended September 30, 2019 and provided a

  7. Catalyst Biosciences Announces Poster Presentations at the 61st Annual American Society of Hematology Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications, today

  8. Catalyst Biosciences Provides DalcA Phase 2b Trial Update

    SOUTH SAN FRANCISCO, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today provided an update on enrollment in its Phase 2b study of dalcinonacog alfa (DalcA), a next-generation

  9. 22NW: Catalyst Biosciences Needs Change Now

    SEATTLE, Oct. 2, 2019 /PRNewswire/ -- Dear Catalyst Biosciences, Inc. Shareholders: 22NW, LP ("22NW" or "we") is one of the largest shareholders of Catalyst Biosciences, Inc (the "Company")

  10. 22NW: Catalyst Biosciences Needs Change Now

    SEATTLE, Sept. 27, 2019 /PRNewswire/ -- Dear Catalyst Biosciences, Inc. Shareholders: 22NW, LP ("22NW" or "we" or "us") is one of the largest shareholders of Catalyst Biosciences, Inc (the

  11. Catalyst Biosciences to Present at the Cantor Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will

  12. Catalyst Biosciences to Present at the 2019 ASBMB Symposium on Serine Proteases in Pericellular Proteolysis and Signaling Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced an oral presentation at the 2019 American Society for Biochemistry and Molecular Biology (ASBMB)

  13. Catalyst Biosciences Announces Transition of Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that its chief financial officer, Fletcher Payne, will be stepping down from the Company to